ABSTRACT Background: Prostate cancer incidence varies 60-fold globally, which suggests the roles of lifestyle and dietary factors in its cause. To our knowledge, a comprehensive assessment of the association between fish consumption and prostate cancer incidence and mortality has not been reported. Objective: We conducted a meta-analysis of fish intake and prostate cancer by focusing on the incidence of prostate cancer and prostate cancer-specific mortality and included subgroup analyses based on race, fish type, method of fish preparation, and high-grade and highstage cancer. Design: We searched MEDLINE and EMBASE databases (May 2009) for case-control and cohort studies that assessed fish intake and prostate cancer risk. Two authors independently assessed eligibility and extracted data. Results: There was no association between fish consumption and a significant reduction in prostate cancer incidence [12 case-control studies (n ¼ 5777 cases and 9805 control subjects), odds ratio (OR): 0.85; 95% CI: 0.72, 1.00; and 12 cohort studies (n ¼ 445,820), relative risk (RR): 1.01; 95% CI: 0.90, 1.14]. It was not possible to perform a meta-analysis for high-grade disease (one case-control study, OR: 1.44; 95% CI: 0.58, 3.03), locally advanced disease (one cohort study, RR: 0.80; 95% CI: 0.61, 1.13), or metastatic disease (one cohort study, RR: 0.56; 95% CI: 0.37, 0.86). There was an association between fish consumption and a significant 63% reduction in prostate cancer-specific mortality [4 cohort studies (n ¼ 49,661), RR: 0.37; 95% CI: 0.18, 0.74]. Conclusion: Our analyses provide no strong evidence of a protective association of fish consumption with prostate cancer incidence but showed a significant 63% reduction in prostate cancer-specific mortality.
INTRODUCTION
Prostate cancer incidence and mortality varies up to 60-fold globally. Although part of the variation may be explained by differences in diagnostic intensity, the large variation in mortality across countries may also suggest the role of lifestyle and dietary factors in its cause (1) (2) (3) . The dramatic increase in prostate cancer incidence and mortality observed in immigrants from low-risk to high-risk countries points to this hypothesis (1, 2) . A role of fish intake and prostate cancer has been studied in several settings. Populations with a high consumption of fish, such as in populations in Japan and in Alaskan Eskimos, have lower rates of prostate cancer than populations with Western diets, in which fish intake is generally lower (3) (4) (5) . Fish are rich in the longchain marine omega-3 polyunsaturated fatty acids, which may lower prostate cancer risk and progression by reducing inflammatory processes (6) .
The results of several case-control and prospective cohort studies of the association between fish intake and prostate cancer risk have been divergent. Previous qualitative reviews, which were limited to a small number of studies and focused strictly on cancer incidence, came to differing conclusions on the potential protective role of fish (7, 8) . To our knowledge, there has been no comprehensive quantitative assessment of the associations of fish consumption with prostate cancer incidence. Moreover, prostate cancer varies considerably in its biologic potential, and thus, an evaluation of fish and cancer prevention should include prostate cancer defined by stage and grade. In response, we conducted the first meta-analysis of fish intake and prostate cancer by looking at published case-control and cohort studies. We focused on the incidence of prostate cancer and prostate cancer-specific mortality and included subgroup analyses based on race, type of fish, method of fish preparation, and cancer characteristics.
METHODS

Study identification
The methods of the analysis and inclusion criteria were specified in advance and documented in a protocol. Our report follows the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (9) . In collaboration with a professional librarian, we created individualized search strategies for 3 electronic databases as follows: MEDLINE (www.ncbi.nlm.nih.gov/sites/entrez) (January 1966 to May 2009), EMBASE (www.embase.com) (1947 to May 2009), and ProQuest Dissertations and Theses Database (1861-2009), which is a worldwide database of graduate-student dissertations and theses. We used the following MEDLINE Medical Subject Headings terms: ''fishes'' OR ''fish oils'' OR ''seafood'' AND ''prostatic neoplasms,'' along with text word searches for the following range of synonyms: neoplasms, tumors, or cancer of the prostate. For the EMBASE search, search terms included prostate, cancer, neoplasm, tumor, fish, seafood, and derivatives. We also searched reference lists of included articles, reviews, and book chapters and contacted experts to capture additional eligible studies.
Inclusion and exclusion criteria
We searched the databases for case-control and cohort studies that assessed fish intake in relation to histologically confirmed prostate cancer without language restrictions. Cross-sectional and ecologic analyses were excluded, as were studies without informative effect estimates [eg, without both exposed and unexposed cases (10) ].
Study selection
Two authors (KMS and DCW) independently assessed abstracts of potentially eligible case-control and cohort studies that investigated fish intake and the risk of prostate cancer. The primary outcome was prostate cancer incidence. Secondary outcomes were as follows: 1) aggressive disease based on a high grade (Gleason grade 7) or advanced stage (stage T3a or positive lymph nodes or metastases) and 2) prostate cancerspecific mortality. Although a meta-analysis was not possible with only a single study, we reported results of individual studies for high-grade and high-stage prostate cancer to ensure comprehensiveness. In the event of uncertainty about study eligibility based on abstracts alone, the reviewers examined the full text of articles. Discrepancies as to study eligibility occurred in 6 cases and were resolved by consensus.
We completed the initial MEDLINE and EMBASE search in May 2009 and found 627 articles. From these, we selected 37 articles for further assessment and rejected 18 articles after manuscript review because they did not meet he inclusion criteria, which left 19 articles for analyses (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (Figure 1) . No new articles were found in the ProQuest Dissertations and Theses Database. We selected an additional 8 articles (30-37) from reference lists of 20 reviews and already selected articles and another 4 articles (38-41) from the reference list of a book chapter (42) . No new articles were obtained by discussion with 2 experts in the field. Of the total 31 articles, one article was in Japanese (24) and the remainder of the articles were in English.
We identified 17 case-control studies (13, 16-22, 26, 27, 29-31, 35, 36, 39, 40) (Table 1 ) and 14 cohort studies (11, 12, 14, 15, 23-25, 28, 32-34, 37, 38, 41) (Table 2 ). Twelve case-control studies considered total fish intake as the main exposure (13, 16, 17, 19, 26, 27, 29-31, 35, 36, 39) , whereas other studies investigated only certain fish types. Two studies (18, 40) presented data specifically on fatty fish consumption (eg, salmon, herring, and mackerel), and 4 studies (19) (20) (21) (22) presented data on preserved fish (smoked, dried, and salted). All case-control studies assessed the total prostate cancer incidence as an outcome. Amin et al (13) also presented data on high-grade disease.
Studies were performed in Canada (14, 20, 22, 32, 36) , Sweden (18, 39) , Italy (17, 27) , United Kingdom (40), Poland (22) , Taiwan (16, 35) , China (20) , Japan (26) , Nigeria (29) , and Uruguay (30) . There was a variation in the median amounts of fish consumed in the study populations. The duration of fish consumption measured also varied and included the past 1 wk (13, 27) and 1 (18, 19, (30) (31) (32) , 2 (20, 22, 36) , 5 (20, 26, 40) , 10 (16) , and 20 y (22, 39) .
All 14 cohort studies of prostate cancer considered total fish consumption as the main exposure. All but 2 cohort studies (23, 37) estimated the incidence of prostate cancer diagnosis; these studies used prostate cancer mortality as the primary endpoint. The studies presented variable data on clinical cancer characteristics. Park et al (33) used a combined high-grade and highstage disease. Augustsson et al (14) reported high-stage and metastatic disease separately. Rohrmann et al (34) combined prostate cancer mortality and high-stage disease. Four studies reported prostate cancer mortality (16, 24, 29, 37) . Five cohort studies focused on Asian populations living in the United States (33, 41) and Japan (12, 23, 24) . The remaining studies were based in the United States (14, 15, 32, 34, 37, 38) , Netherlands (25) , Sweden (28) , and 8 European countries (11) (ie, Denmark, Germany, Greece, Italy, Netherlands, Spain, Sweden, and United Kingdom). There was variation in the median amount of fish consumed across the study populations. The duration of fish consumption measured also varied and included current dietary practices (12, 14, 28, 34) , the past 24 h (33, 41), 1 wk (38), 1 mo (37), and 1 y (13, 16, 24, 26, 34) .
Data extraction
Two authors (KMS and DCW) independently extracted data in 4 categories from each eligible study as follows: 1) study design [country, case-control or cohort study, total number of case and control subjects or cohort size, year that the study ended, method FIGURE 1. Flowchart of study search. For some reports, more than one exclusion criterion was noted; therefore, numbers do not add to 608. Middle exposure category in control subjects. ORs and 95% CIs to compare the first and fourth quartile were derived from ORs in the article, which used quartile 3 as the reference.
of dietary assessment (quantitative compared with qualitative assessment), time frame of dietary assessment, excluded pathology, study duration, and covariates used in multivariate analysis]; 2) population (race composition, mean age at enrollment, and percentage who refused to participate or were lost to follow-up); 3), exposure (all, fresh, salted, dry, smoked, fatty, and canned fish); and 4) outcome [adjusted odds ratio (OR) or relative risk (RR) for extreme comparison groups; 95% CIs for prostate cancer incidence, high grade, high stage, and prostate cancer-specific mortality; and race-specific ORs, RRs, and 95% CIs, if available]. In one case (28), the lowest quantile was not the reference, and the effect measures and CIs were recalculated to allow comparisons with other studies that used the lowest quantile as the reference. Participation rates and lengths of followup and dietary assessment were not available for all studies. The 2 authors resolved 4 discrepancies in data extraction by repeating the study review and reached a consensus. In case more than one published article described the same study population, exposure, and outcome, the most recent and complete manuscript was analyzed. The single study published in Japanese (24) was analyzed by a native speaker familiar with medical terminology and meta-analysis design.
Statistics
We estimated the summary association between fish consumption and prostate cancer incidence in case-control and cohort studies separately. We also conducted separate subgroup analyses of prostate cancer incidence by restricting the analysis to studies with prepared (ie, salted, dry, and smoked) or fatty fish as an exposure and to studies of Asian populations. In addition, we performed analyses for the association of fish consumption with high-grade, high-stage, and fatal prostate cancer (clinical characteristics). We performed all statistical analyses with Stata v.10.1 (StataCorp, College Station, TX). We used a random effects model for our meta-analysis (METAN command in Stata v.10.1; StataCorp) to account for within-study and between-study variances (43) , which were potentially driven by interstudy variations in race, use of prostate specific antigen (PSA) screening, and types of fish assessed across studies.
We performed a sensitivity analysis of the influence of individual studies on the summary estimate by repeating the metaanalysis but excluding one study at a time. We evaluated the heterogeneity among studies with the Cochrane Q test (significant at P , 0.1). Because this test has limited sensitivity, which varies with the number of studies, we also quantified heterogeneity with the I 2 statistic (44), which represents the percentage of total variation across studies because of betweenstudy heterogeneity.
We used meta-regression (METAREG command in Stata v.10.1; StataCorp) to look for sources of heterogeneity across studies (significant at P , 0.2). The meta-regression analysis variables included the type of controls used in case-control studies (hospital compared with community), race (majority of the study population was Asian compared with other), total number of participants (continuous variable), whether results were corrected for family history of prostate cancer, exposure scale (qualitative compared with quantitative), and whether the last prostate cancer diagnosis was made after 1990 (ie, the approximate date the PSA screening was introduced) (45) . Publication bias was tested by using Egger (46) and Begg (47) analyses and a visual inspection of the funnel plot.
RESULTS
Prostate cancer risk
Case-control studies
Based on data from 12 case-cohort studies (13, 16, 17, 19, 26,  27, 29-31, 35, 36, 39 ) of 5777 cases of prostate cancer and 9805 control subjects, a high consumption of fish was marginally associated with a reduction in total prostate cancer (pooled OR: 0.85; 95% CI: 0.72, 1.00; P ¼ 0.05) when extreme quantiles of fish consumption were compared (Figure 2) . CIs of all individual study results included the pooled result. Pooled ORs from the sensitivity analysis ranged from 0.82 (95% CI: 0.71, 0.94) after excluding Andersson et al (39) to 0.88 (95% CI: 0.74, 1.05) after excluding Jain et al (31) , which indicated that some studies significantly influenced the pooled estimate. Indeed, the removal of any of 7 studies (13, 17, 19, 26, 27, 30, 31) from the sensitivity analysis resulted in the protective association with fish consumption not being statistically significant at the 0.05 level (data not shown). We found significant heterogeneity among studies (P ¼ 0.05), with 44% (95% CI: 0, 72) of the heterogeneity due to of variability among studies. In the meta-regression analysis, none of the 6 variables assessed were significantly related to the strength of the association between fish intake and prostate cancer risk (P 0.38). The Begg (P ¼ 0.68) and Egger (P ¼ 0.62) tests, as well as visual inspection of the funnel plot (not shown), did not suggest a publication bias.
The subgroup analysis for preserved fish (19) (20) (21) (22) showed no reduced risk (OR: 0.86; 95% CI: 0.53, 1.42) ( Table 3) . Approximately 77% (95% CI: 37, 92) of the heterogeneity was due to variability among studies (P ¼ 0.005). The pooled OR of the 2 studies with data on fatty fish (18, 40) showed no protective association (OR: 0.57; 95% CI: 0.29, 1.12; P ¼ 0.10). The test FIGURE 2. Pooled results for 12 case-control studies of total fish consumption and prostate cancer incidence. Before rounding, the summary odds ratio (OR) 95% CI contained 1.00, and P was rounded down to 0.05.
for heterogeneity was marginally significant (P ¼ 0.10), although the Cochrane Q test needs to be interpreted cautiously with only 2 studies. When the analysis was restricted to only the 3 casecontrol studies of Asian populations (16, 26, 35) , there was no evidence that fish consumption provided a protective association with prostate incidence (OR: 0.92; 95% CI: 0.57, 1.49; P ¼ 0.72). There was no evidence of heterogeneity (P ¼ 0.12).
Cohort studies
Data from 12 cohort studies (11, 12, 14, 15, 24, 25, 28, 32-34, 38, 41) of 445,820 men and 13,924 prostate cancers showed no association between a higher total intake of fish and prostate cancer incidence (pooled RR: 1.01; 95% CI: 0.90, 1.14; P ¼ 0.83) (Figure 3) . However, there was a significant heterogeneity in the study population (P ¼ 0.005) of which 59% (95% CI: 22, 78) of the heterogeneity was due to interstudy variability. In the sensitivity analysis, pooled RRs ranged from 0.99 (95% CI: 0.89, 1.12) after excluding Allen et al (12) to 1.04 (95% CI: 0.98, 1.11) after excluding Terry et al (28) , which indicated that the overall results were not significantly influenced by any one study. In the meta-regression analysis, a study by Terry et al (28) that used a qualitative scale to measure fish consumption (ie, never/seldom; small, moderate, and large part) reported a significantly greater inverse association between fish intake and the risk of prostate cancer (P ¼ 0.02). After excluding this study from the analysis, the heterogeneity was no longer significant (P ¼ 0.41; I 2 ¼ 3%; 95% CI: 0, 61), and the pooled RR did not change (pooled RR: 1.04; 95% CI: 0.98, 1.11). The Begg (P ¼ 0.78) and Egger (P ¼ 0.84) tests, along with the funnel plot (not shown), did not suggest a publication bias.
In the subset analysis of the 4 Asian-population cohorts (12, 24, 33, 41) , fish consumption was not associated with prostate cancer incidence (RR: 1.06; 95% CI: 0.76, 1.49). There was no significant heterogeneity (P ¼ 0.10; I 2 ¼ 53%; 95% CI: 0, 83).
In the sensitivity analysis, no studies were significantly influential because RRs ranged from 0.93 (95% CI: 0.75, 1.15) after excluding Allen et al (12) to 1.17 (95% CI: 0.79, 1.74) after excluding Sato et al (24) .
Prostate cancer by clinical characteristics
High-grade prostate cancer
The only case-control study to report RR estimates based on tumor grade reported fish consumption to have an insignificant 
High-stage prostate cancer
Of all studies reviewed, only the cohort study by Augustsson et al (14) presented RR estimates strictly for high stage disease without combining it with high-grade (33) or fatal (34) disease. Augustsson et al (14) showed fish consumption to have a significant risk reduction of 44% for metastatic disease (RR: 0.56; 95% CI: 0.37, 0.86) but no significant protective association with locally advanced prostate cancer (RR: 0.83; 95% CI: 0.61, 1.13). With the use of any definition of advanced prostate cancer, pooled results of 3 cohort studies (14, 33, 34) did not indicate that fish consumption had a significant protective association with high-stage disease (RR: 0.80; 95% CI: 0.50, 1.28). The pooled finding must be interpreted with caution because the 3 studies measured slightly different outcomes. Another cohort study (25) that modeled fish consumption as a continuous variable showed fish consumption of 25 g fish/wk to be unassociated with highstage disease (RR: 1.08; 95% CI: 0.87, 1.33).
Prostate cancer-specific mortality
Pooling the results of the 4 cohort studies (15, 23, 28, 37 ) of 49,661 men and 740 fatal prostate cancers, a high consumption of fish was associated with a significant 63% reduction in fatal disease (RR: 0.37; 95% CI: 0.18, 0.74; P ¼ 0.005) (Figure 4) . A sensitivity analysis revealed that none of the studies significantly influenced the pooled estimate, with the pooled RR ranging from 0.28 (95% CI: 0.13, 0.57) after excluding Terry et al (28) to 0.49 (95% CI: 0.28, 0.92) after excluding Chavarro et al (15) .
There was significant heterogeneity between studies (P ¼ 0.001; I 2 ¼ 83%; 95% CI: 55, 93). In univariate meta-regression analysis, larger studies reported a weaker inverse association with prostate-cancer mortality (P ¼ 0.15). With stratification on the number of study participants, studies (15, 37) with .17,000 participants showed fish consumption to have a 34% protective association (RR: 0.66; 95% CI: 0.43, 1.01), although the results were not significant at the 0.05 level. Studies (23, 28) with ,7000 participants showed a significant pooled risk reduction of 80% (RR: 0.20; 95% CI: 0.09, 0.43). The Begg (P ¼ 0.17) and Egger (P ¼ 0.22) tests, as well as visual inspection of the funnel plot (not shown), did not suggest a publication bias.
DISCUSSION
The results of this quantitative meta-analysis provided limited evidence for a protective association of total fish consumption with prostate cancer incidence. Although the pooled analysis from the case-control studies suggested a small reduction in risk, the results from the cohort studies were null. The findings were similar regardless of race, type of fish, and preparation method. There was no protective association evident for fish consumption and the risk of high-grade or locally advanced prostate cancer.
For prostate cancer progression, total fish intake was associated with a 44% reduction in metastatic disease (14) . It was also associated with a 63% reduction in prostate cancer-specific mortality (15, 23, 28, 37) . There was a significant heterogeneity in study results, which was partly explained by sizes of the study populations. The associations observed were closer to null in larger studies. The statistically and clinically significant reduction in mortality was consistent with the results of a cohort study (48) of 46,465 Japanese men who were followed between 1989 and 2003 that was not included in this meta-analysis because the results were presented separately for fresh and preserved fish without an overall association with fish consumption. This prevented pooling of results with other studies. In the study, fresh-fish consumption, but not preserved-fish consumption, was associated with a 39% (95% CI: 5, 61) reduction in prostate cancer mortality.
It has been proposed that antiinflammatory fish fatty acids may lower prostate cancer risk (6) . Fatty acids regulate the production of proinflammatory prostaglandins and hydroxyeicosatetraenoic acid via the cyclooxygense and lipoxygenese pathways (6) . These pathways play a major role in inflammation, proliferation, and angiogenesis, which are variables that are key drivers in cancer progression. There is support from animal models and cell-line data that long-chain n23 polyunsaturated fatty acids have been linked specifically to the reduction of the progression of cancer cells (49, 50) . Thus, it makes sense that the antiinflammatory role of fish is specific to the prevention of cancer progression. In our study, fish consumption was not associated with a lower incidence of all prostate cancer, but it may be related to decreased aggressive, clinically relevant disease. Fish consumption may decrease cancer-specific mortality by preventing metastatic disease. Our findings for metastatic and lethal disease need to be interpreted with caution because of the few studies available.
We observed a significant heterogeneity among studies, whether because of the type of scale used to measure fish consumption or the study sample size. Interestingly, studies completed before or after the introduction of PSA screening had similar results. PSA testing has been described as a possible confounder in studies of prostate cancer and lifestyle factors (42) because men who get the blood test may be more likely to take up healthy lifestyles, including fish consumption. Moreover, cancers diagnosed by PSA screening often differ from clinically significant tumors. Note that none of the studies used in the meta-analysis reported the proportion of cases diagnosed by PSA testing or adjusted for it in their analysis. Also, only 3 of 12 case-control studies (13, 20, 36 ) and 2 of 12 cohort studies (25, 33) controlled for a family history of prostate cancer in their analyses. It is unlikely that a family history of prostate cancer is a strong confounder because it is not strongly related to both fish consumption and disease risk. Although strongly linked to prostate cancer incidence, a family history of prostate cancer is probably not related to large differences in the prevalence of fish consumption. The hypothesis of the preventative effect of fish consumption has not received widespread media or public health attention. In our analyses, results of studies of prostate cancer incidence and mortality that did and did not adjust for a family history of prostate cancer did not differ in the meta-regression.
A strength of our meta-analysis is that we captured the maximal number of published and unpublished studies on the topic by using multiple avenues for finding articles. Two investigators independently performed the article identification, data extraction, and verification and resolved all discrepancies.
Our study has important limitations. We assessed total fish consumption because of the relatively large number of studies on the topic, which made them amenable to a meta-analysis. However, total fish consumption includes fatty fish (eg, salmon and tuna), which are much higher in the fatty acids docosahexaenoic acid and eicosapentaenoic acid, as well as fish that are lower in marine fatty acids (eg, cod and flounder) (51) . Moreover, fish intake may include fish prepared in a number of methods, including deep-fried fish, that increase the intake of fats that may be associated with an increased prostate cancer risk. Our pooled estimates represent the combination of different types of fish that may have different effects on prostate cancer. Intakes of different types of fish vary considerably across countries, thus providing one explanation for the heterogeneity across studies. Although our meta-analysis provided little evidence of a protective association between prostate cancer incidence and total fish consumption, it cannot rule out a protective association with high consumption of marine fatty acids or fatty fish.
As with other meta-analyses, our analyses suffer from the same limitations as all observational studies. Although analysis of our primary outcome, prostate cancer incidence, was based on many studies, fewer studies were available for the secondary outcomes of high-grade, high stage, and lethal disease. As such, the pooled estimates were more susceptible to the influence from individual studies. Individual studies could have been prone to selection biases. Information on the percentages of subjects who refused to participate in case-control studies and dropout rates in cohort studies were not available for all studies. However, for the 7 cohort studies with published values, the loss to follow-up was low and ranged from ,5% (15, 25, 32, 34, 41) to 11% (38) and 17% (12) . In our analyses, we were unable to assess dose responses because the number of cases and noncases by stratum were often missing in studies, whereas various scales were used to assess fish consumption. The use of different scales made it difficult to directly compare studies based on the highest intake of fish assessed, which may correlate to the amount of marine fatty acids consumed. A race-specific subgroup meta-analysis was also only possible for Asian populations because of an insufficient number of studies with results stratified by race. The tests of heterogeneity and publication bias used were underpowered, and although a publication bias was not detected, we could not rule it out.
In conclusion, our analyses of observational studies provides little evidence of a protective association of fish consumption with prostate cancer incidence. Data were sparse on high-grade and locally advanced disease but suggested no significant protective association. There is evidence that high fish consumption is associated with a 63% reduction in prostate cancer-specific mortality, which is possibly mediated by decreased metastatic disease. Because the number of studies available for a secondary outcome assessment was small, additional studies of aggressive and fatal disease are needed.
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